Mixed Lineage Kinase 2 (MLK2) in tumor angiogenesis
- Institution
- BRIGHAM AND WOMEN'S HOSPITAL, MA
- Principal investigator
- Shashi Kant
- Funding
- $83K
- Duration
- 2025–2026
Moonbase score
Still being scored
Abstract
Project Summary Cancer is one of the leading causes of death in the USA. The study examines the role of Mixed Lineage Kinase 2 (MLK2) in tumor angiogenesis, a process vital for cancer growth. Hypoxic condition in solid tumor activates stress pathway of MLK2. MLK2, abundantly present in the endothelium, is shown to be essential for endothelial proliferation, migration, and angiogenesis. Lack of MLK2 impairs tumor growth in mouse models and increases miR-146a levels, which suppresses angiogenic factors like VEGF, adversely affecting angiogenesis and endothelial cell proliferation. Given that miR-146a overexpression in endothelial cells leads to similar deficiencies, the study suggests that MLK2's regulatory effect on miR-146a is crucial for endothelial functions and tumor angiogenesis.
LOADING MOONBASE SCORE
Questions for BRIGHAM AND WOMEN'S HOSPITAL
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · University of Texas Hlth Ctr at Tyler48
Short course combination regimens for treatment of Mycobacterium avium pulmonary disease: a translational bench-to-bedside approach
Shashi Kant · $549K · 2023–2028
- NIH · Brigham and Women'S Hospital64
Making the invisible visible: An automated clinical decision support tool for Intimate Partner Violence Risk and Severity Prediction (AIRS)
Bharti Khurana · $796K · 2022–2027
- NIH · Brigham and Women'S Hospital60
Mind the gaps: Pharmacokinetic research to advance pediatric HIV/TB cotreatment and TB prevention
Holly Elizabeth Rawizza · $190K · 2022–2028